Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 81,866 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $90.13, for a total transaction of $7,378,582.58. Following the completion of the transaction, the director directly owned 675,341 shares of the company’s stock, valued at approximately $60,868,484.33. The trade was a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.04, for a total value of $61,725.12.
• On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.23, for a total value of $556,594.23.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded down $0.24 during mid-day trading on Wednesday, hitting $86.11. 1,043,150 shares of the stock traded hands, compared to its average volume of 809,415. The company has a market cap of $7.03 billion, a price-to-earnings ratio of -23.40 and a beta of 2.20. The stock has a fifty day moving average price of $78.69 and a 200-day moving average price of $66.27. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same period in the prior year, the business posted ($0.88) EPS. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Truist Financial boosted their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. HC Wainwright boosted their price target on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Stifel Nicolaus set a $114.00 price target on Kymera Therapeutics in a research note on Monday, December 8th. Citigroup lifted their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday. Finally, BTIG Research dropped their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE raised its stake in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after buying an additional 248 shares during the last quarter. Larson Financial Group LLC increased its holdings in Kymera Therapeutics by 36.9% in the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in Kymera Therapeutics by 3.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock worth $985,000 after buying an additional 410 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.